Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This partially randomized phase Ib/II trial studies the side effects and best dose of
selinexor when given together with gemcitabine and nab-paclitaxel, and to see how well they
work in treating patients with pancreatic cancer that has spread to other parts of the body
(metastatic). Drugs used in chemotherapy, such as selinexor, gemcitabine and nab-paclitaxel,
work in different ways to stop the growth of tumor cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading.